Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alprostadil Liposome for Prevention of Contrast-Induced Acute Kidney Injury in Elective PCI
CTR20221833Phase 2Terminated
- Sponsor
- CSPC Pharmaceutical Group
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Vasostenoon in acute kidney failure (AKF), sponsored by CSPC Pharmaceutical Group. Started Jul 2022; status: terminated.
02
Drugs
Vasostenoon
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on CTR20221833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221833.